知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.017 秒)

    Crystalline forms of valbenazine salts
    1.
    发明授权
    Crystalline forms of valbenazine salts 有权

    公开(公告)号：US10954235B2

    公开(公告)日：2021-03-23

    申请号：US16488735

    申请日：2018-02-01

    申请人： Sandoz AG

    发明人： Christoph Langes ,  Ulrich Griesser ,  Erwin Schreiner ,  Marijan Stefinovic

    IPC分类号： C07D471/06 ,  A61K31/4745 ,  C07D471/04

    摘要： The present invention relates to crystalline valbenazine ditosylate, in particular to a crystalline hydrate of valbenazine ditosylate and a crystalline anhydrate of valbenazine ditosylate, and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline hydrate or the crystalline anhydrate, preferably in an effective and/or predetermined amount and to the use of said pharmaceutical composition as a medicament, in particular for the treatment of hyperkinetic movement disorders such as tardive dyskinesia.

    Process for the preparation of form III of Vilazodone hydrochloride
    2.
    发明申请
    Process for the preparation of form III of Vilazodone hydrochloride 有权
    制备盐酸维拉索酮III型的方法

    公开(公告)号：US20150018370A1

    公开(公告)日：2015-01-15

    申请号：US14326921

    申请日：2014-07-09

    申请人： Sandoz AG

    发明人： Marijan Stefinovic ,  Clemens Haefele ,  Ulrich J. Griesser

    IPC分类号： C07D405/12

    CPC分类号： C07D405/12

    摘要： The invention relates to a new solvate, Vilazodone hydrochloride monoethanol monohydrate solvate, and to a process for the preparation of polymorphic form III of Vilazodone hydrochloride via the Vilazodone hydrochloride monoethanol monohydrate solvate.

    摘要翻译： 本发明涉及一种新的溶剂合物，盐酸维拉酮酮单乙醇一水合物溶剂合物，以及通过盐酸维拉唑酮单乙醇一水合物溶剂化物制备盐酸维拉唑酮多晶型III的方法。

    NOVEL FORMS OF TELAPREVIR
    4.
    发明申请
    NOVEL FORMS OF TELAPREVIR 审中-公开
    新形式的TELAPREVIR

    公开(公告)号：US20160039871A1

    公开(公告)日：2016-02-11

    申请号：US14652816

    申请日：2013-12-20

    申请人： SANDOZ AG

    发明人： Marijan Stefinovic ,  Christoph Langes ,  Ulrich Griesser

    IPC分类号： C07K5/103

    CPC分类号： C07K5/1008 ,  A61K38/00 ,  C07D403/12 ,  C07K5/1016 ,  C07K2299/00

    摘要： The invention relates to an amorphous form of telaprevir, its preparation via novel crystalline Form C of telaprevir (also referred to as “crystalline Form C” or “Form C”), and telaprevir compositions comprising said amorphous form and Form C. Furthermore, the present invention relates to the use of said amorphous telaprevir, telaprevir composition and Form C of telaprevir for the preparation of medicaments such as anti-hepatitis C medicaments. Moreover, the present invention relates to pharmaceutical compositions and dosage forms comprising a pharmaceutically effective amount of said novel forms for use in treating patients suffering from hepatitis C virus.

    摘要翻译： 本发明涉及非特异形式的特拉匹韦，其通过特拉匹韦（也称为“结晶形式C”或“形式C”）的新型结晶形式C的制备，以及包含所述无定形形式和形式C的特拉匹韦组合物。此外， 本发明涉及所述非晶特拉匹韦，特拉匹韦组合物和特拉匹韦形式C用于制备药物如抗丙型肝炎药物的用途。 此外，本发明涉及药物组合物和剂型，其包含用于治疗患有丙型肝炎病毒的患者的药学有效量的所述新形式。

    Process for the preparation of form III of vilazodone hydrochloride
    5.
    发明授权
    Process for the preparation of form III of vilazodone hydrochloride 有权
    盐酸维拉唑酮形式III的制备方法

    公开(公告)号：US09145400B2

    公开(公告)日：2015-09-29

    申请号：US14326921

    申请日：2014-07-09

    申请人： Sandoz AG

    发明人： Marijan Stefinovic ,  Clemens Haefele ,  Ulrich J. Griesser

    IPC分类号： C07D405/12

    CPC分类号： C07D405/12

    摘要： The invention relates to a new solvate, Vilazodone hydrochloride monoethanol monohydrate solvate, and to a process for the preparation of polymorphic form III of Vilazodone hydrochloride via the Vilazodone hydrochloride monoethanol monohydrate solvate.

    摘要翻译： 本发明涉及一种新的溶剂合物，盐酸维拉酮酮单乙醇一水合物溶剂合物，以及通过盐酸维拉唑酮单乙醇一水合物溶剂化物制备盐酸维拉唑酮多晶型III的方法。

    Crystalline Forms of Valbenazine Salts
    7.
    发明申请
    Crystalline Forms of Valbenazine Salts 审中-公开

    公开(公告)号：US20200062750A1

    公开(公告)日：2020-02-27

    申请号：US16488735

    申请日：2018-02-01

    申请人： Sandoz AG

    发明人： Christoph Langes ,  Ulrich Griesser ,  Erwin Schreiner ,  Marijan Stefinovic

    IPC分类号： C07D471/04

    摘要： The present invention relates to crystalline valbenazine ditosylate, in particular to a crystalline hydrate of valbenazine ditosylate and a crystalline anhydrate of valbenazine ditosylate, and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline hydrate or the crystalline anhydrate, preferably in an effective and/or predetermined amount and to the use of said pharmaceutical composition as a medicament, in particular for the treatment of hyperkinetic movement disorders such as tardive dyskinesia.

    Solid Dispersion Comprising μ-Opioid Antagonists
    9.
    发明申请
    Solid Dispersion Comprising μ-Opioid Antagonists 审中-公开

    公开(公告)号：US20180153879A1

    公开(公告)日：2018-06-07

    申请号：US15598662

    申请日：2017-05-18

    申请人： Sandoz AG

    发明人： Marijan Stefinovic ,  Hayley Reece

    IPC分类号： A61K31/485 ,  A61K31/765 ,  A61K33/00 ,  A61K9/10 ,  A61K9/00 ,  A61K9/20

    CPC分类号： A61K31/485 ,  A61K9/0053 ,  A61K9/10 ,  A61K9/146 ,  A61K9/2027 ,  A61K31/765 ,  A61K33/00

    摘要： The present invention relates to a solid dispersion comprising, preferably consisting of, naloxegol salts in amorphous form and at least one pharmaceutically acceptable matrix compound and wherein the matrix compound is (i) an organic polymer, or (ii) a silicon-based inorganic adsorbent. Further, the present invention also relates to a process for preparing a solid dispersion comprising naloxegol in amorphous form and at least one pharmaceutically acceptable matrix compound, as well as to a solid dispersion obtained or obtainable by said process. Further, the present invention relates to a pharmaceutical composition comprising such solid dispersion as well as a pharmaceutical composition for use as p-opioid antagonists.

    Co-Crystals Comprising Levothyroxine And A Dicarboxylic Acid
    10.
    发明申请
    Co-Crystals Comprising Levothyroxine And A Dicarboxylic Acid 有权

    公开(公告)号：US20210395186A1

    公开(公告)日：2021-12-23

    申请号：US17285653

    申请日：2019-10-16

    申请人： Sandoz AG

    发明人： Marijan Stefinovic ,  Dennis Dimo Enkelmann ,  Ulrich Griesser ,  Thomas Gelbrich

    IPC分类号： C07C229/36 ,  C07C55/02

    摘要： The present invention relates to co-crystals comprising levothyroxine and a dicarboxylic acid, preferably L-tartaric acid or oxalic acid, and processes for the preparation thereof. Furthermore, the invention relates to a pharmaceutical composition comprising a co-crystal of the present invention, preferably the co-crystal comprising levothyroxine and L-tartaric acid or oxalic acid, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of hypothyroidism.